1 |
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman H.H. Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2011;7(3):270-279. https://doi.org/10.1016/j.jalz.2011.03.008
DOI
|
2 |
Langa KM, Levine D. The diagnosis and management of mild cognitive impairment: a clinical review. Journal of the American Medical Association. 2014;312(23):2551-2561. https://doi.org/10.1001/jama.2014.13806
DOI
|
3 |
Morley JE. An overview of cognitive impairment. Clinics in Geriatric Medicine. 2018;34(4):505-513. https://doi.org/10.1016/j.cger.2018.06.003
DOI
|
4 |
Prendecki M, Kowalska M, Toton E, Kozubski W. Genetic editing and pharmacogenetics in current and future therapy of neurocognitive disorders. Current Alzheimer Research. 2020;17(3):238-258. https://doi.org/10.2174/1567205017666200422152440
DOI
|
5 |
Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. British Medical Journal. 2019;367:l6217. https://doi.org/10.1136/bmj.l6217
DOI
|
6 |
Lopez OL, Kuller LH. Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer's disease and other dementias. In Dekosky ST, Asthana S, editor. Handbook of Clinical Neurology. Amsterdam: Elsevier; 2019. p.139-148.
|
7 |
Chakrabarti S, Khemka KV, Banerjee A, Chatterjee G, Ganguly A, Biswas A. Metabolic risk factors of sporadic Alzheimer's disease: implications in the pathology, pathogenesis and treatment. Aging and Disease. 2015;6(4):282-299. https://doi.org/10.14336/AD.2014.002
DOI
|
8 |
Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Design, Development and Therapy. 2017;11:797-810. https://doi.org/10.2147/DDDT.S130514
DOI
|
9 |
Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opinion on Investigational Drugs.2019;28(11):951-965. https://doi.org/10.1080/13543784.2019.1681398
DOI
|
10 |
Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2008;79(4):368-376. https://doi.org/10.1136/jnnp.2007.131045
DOI
|
11 |
Dubbioso R, Manganelli F, Siebner HR, Lazzaro VD. Fast intracortical sensory-motor integration: a window into the pathophysiology of Parkinson's disease. Frontiers in Human Neuroscience. 2019;13:111. https://doi.org/10.3389/fnhum.2019.00111
DOI
|
12 |
Chou KL, Hurtig HI, Eichler AF. Diagnosis and differential diagnosis of Parkinson disease. Alphen aan den Rijn: Wolters Kluwer; 2020 [cited 2020 June 19]. Available from: https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-parkinson-disease#H130396564.
|
13 |
Chan PC, Lee HH, Hong CT, Hu CJ, Wu D. REM sleep behavior disorder (RBD) in dementia with Lewy Bodies (DLB). Behavioural Neurology. 2018;2018:9421098. https://doi.org/10.1155/2018/9421098
DOI
|
14 |
Truini A, Frontoni M, Cruccu G. Parkinson's disease related pain: a review of recent findings. Journal of Neurology. 2013;260(1):330-334. https://doi.org/10.1007/s00415-012-6754-5
DOI
|
15 |
Gale SA, Acar D, Daffner KR. Dementia. American Journal of Medicine. 2018;131(10):1161-1169. https://doi.org/10.1016/j.amjmed.2018.01.022
DOI
|
16 |
Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. Brain: A Journal of Neurology.2020;143(5):1588-1602. https://doi.org/10.1093/brain/awaa088
DOI
|
17 |
Davis Phinney Foundation. The difference between lewy body dementia, parkinson's disease and alzheimer's disease [Internet]. Louisville (CO): Davis Phinney Foundation; 2018[cited 2020 June 18]. Available from: https://www.davisphinneyfoundation.org/blog/difference-lewy-body-dementia-parkinsons-disease-alzheimers-disease/.
|
18 |
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. https://doi.org/10.1212/WNL.0000000000004058
DOI
|
19 |
Massa F, Arnaldi D, De Cesari F, Girtler N, Brugnolo A, Grazzini M, et al. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging. 2019;76:9-17. https://doi.org/10.1016/j.neurobiolaging.2018.12.001
DOI
|
20 |
Bruijnen CJWH, Dijkstra BAG, Walvoort SJW, Budy MJJ, Beurmanjer H, De Jong C, et al. Psychometric properties of the Montreal Cognitive Assessment (MoCA) in healthy participants aged 18-70. International Journal of Psychiatry in Clinical Practice. 2020;9:1-8. https://doi.org/10.1080/13651501.2020.1746348
DOI
|
21 |
Butler M, Nelson VA, Davila H, Ratner E, Fink HA, Hemmy LS. et al. Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dmentia: a systematic review. Annals of Internal Medicine. 2018;168(1):52-62. https://doi.org/10.7326/M17-1530
DOI
|
22 |
Nasreddine ZS, Patel BB. Validation of Montreal Cognitive Assessment, MoCA, alternate French versions. The Canadian Journal of Neurological Sciences. 2016;43(5):665-671. https://doi.org/10.1017/cjn.2016.273
DOI
|
23 |
Teng EL, Hasegawa K, Homma A, Imai Y, Graves A, Sugimoto K, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. International Psychogeriatrics. 1994;6(1):45-58; https://doi.org/10.1017/s1041610294001602
DOI
|
24 |
Chiu EC, Yip PK, Woo P, Lin YT. Test-retest reliability and minimal detectable change of the Cognitive Abilities Screening Instrument in patients with dementia. PloS One. 2019;14(5):e0216450. https://doi.org/10.1371/journal.pone.0216450
DOI
|
25 |
Leroi I, Vatter S, Carter LA, Smith SJ, Orgeta V, Pliakoff E, et al. Parkinson's-adapted cognitive stimulation therapy: a pilot randomized controlled clinical trial. Therapeutic Advances in Neurological Disorders. 2019;12:1756286419852217. https://doi.org/10.1177/1756286419852217
|
26 |
Rose N, Whitworth A, Smart S, Oliver E, Cartwright J. "I remember when…": The impact of reminiscence therapy on discourse production in older adults with cognitive impairment. International Journal of Language and Pathology. 2020;22(3):359-371 https://doi.org/10.1080/17549507.2020.1747542.
|
27 |
Sanford AM. Mild cognitive impairment. Clinics in Geriatric Medicine. 2017;33(3):325-337. https://doi.org/10.1016/j.cger.2017.02.005
DOI
|